Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer

Takaaki Mizuno, Kenji Tamura(Unknown)

Oncology Letters

October 7, 2020

10.3892/ol.2020.12200

Cited by 21

Related Papers

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

|The Lancet Oncology|2021|412

Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study

|Cancer Science|2019|375

First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid Tumors

|Clinical Cancer Research|2021|97

HER3 protein expression as a risk factor for post‑operative recurrence in patients with early‑stage adenocarcinoma and adenosquamous carcinoma of the cervix

|Oncology Letters|2020|10